1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018

Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018

  • March 2018
  • ID: 5385553
  • Format: PDF
  • Firstword Pharma

Summary

Table of Contents

In the EU5, several of the renal cell carcinoma (RCC) medical affairs teams we surveyed are running neck and neck with at least one rival. The 150 medical oncologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put your team ahead of the competition?

Discover all the ways you can improve your medical affair services in Medical Affairs Reputations: Renal Cell Carcinoma (EU5). Comparing 10 major Renal Cell Carcinoma treatments from Novartis, Roche, Exelixis, Ipsen, Pfizer, Eisai, Bayer, and Bristol-Myers Squibb, this detailed report reveals:
• How medical oncologists rate your team overall, and on 12 key medical affairs services
• Which medical affairs services are most important
• How, and how often medical oncologists want to meet with your team
• What you can do to improve your medical affairs services

It’s time to find out exactly how well your medical affairs team is performing against fierce competition – and establish an action plan to gain competitive advantage.

Top Takeaways
• One team has the lead, but is it big enough? Rated for overall quality of interactions, the leading team is six points ahead of the team in 2nd place. Farther down the pack there are tight races for all other brands.
• Modest performance. Overall, scores are hovering just above neutral, but the top teams earned somewhat positive scores—especially in the areas important to doctors.
• Doctors rely on teams for a range of services. The most important medical affairs services relate to information provision, speaker programmes, and clinical trials.
• Doctors want to see teams in-person and not too often. The report reveals how, and how frequently your team should engage.

Insight into Medical Affairs Teams for These Renal Cell Carcinoma Treatments
• Afinitor (everolimus; Novartis)
• Avastin (bevacizumab; Roche)
• Cabometyx (cabozantinib; Exelixis/Ipsen)
• Inlyta (axitinib; Pfizer)
• Kisplyx (lenvatinib; Eisai)
• Nexavar (sorafenib; Bayer)
• Opdivo (nivolumab; Bristol-Myers Squibb)
• Sutent (sunitinib; Pfizer)
• Torisel (temsirolimus; Pfizer)
• Votrient (pazopanib; Novartis)

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 10 medical affairs teams—answering important questions like:

What do doctors need?
• How, and how often are they using your medical affairs team?
• What services do they consider most important?
• How often should you contact them? What channels are best?

Does your medical affairs team deliver?
• How memorable are your team’s interactions with doctors?
• How do doctors rank your team for performance and satisfaction in 12 key areas?
• How does your team compare to the competition—in each area, and overall?

What needs improvement?
• Are you delivering the services that are most important to doctors?
• Where do you need to improve?
• How can your team enhance its services?

Based on Interviews with Practicing Doctors

We surveyed 150 medical oncologists from EU5 (France, Italy, Germany, Spain, UK) - chosen from the largest community of validated physicians in the world.

All respondents:
• Have been practicing for between 3 and 35 years
• See at least 5 patients a typical month
• Devote at least 50% of their time to direct patient care
• Have interacted with at least one listed product’s medical affairs team in the past 6 months.

We conducted the survey between March 5-8, 2018.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2019-2028

  • $ 1250
  • September 2020
  • 159 pages

KEY FINDINGS The Europe kidney cancer therapeutics and diagnostics market is projected to showcase a CAGR of 5.36% during the forecast period, 2019-2028. The advanced healthcare system in the countries ...

  • Europe
  • France
  • Renal Cancer
  • Diagnostics
  • Industry analysis
  • Cause-Specific Mortality Rate

abexinostat $ 10000 March 2019

NPS+ Renal Cell Carcinoma (US) $ 2765 February 2016

NPS+ Renal Cell Carcinoma (EU5) $ 2765 February 2016


ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on